Cancer Meds in U.S. Are in Short Supply
A record 180 medicines used to treat cancers and a number of other diseases and infections are in short supply in the U.S. this year, and as a result prices for some have skyrocketed to as much as 20 times the original cost.
A record 180 medicines used to treat cancers and a number of other diseases and infections are in short supply in the U.S. this year, and as a result prices for some have skyrocketed to as much as 20 times the original cost.
Some clinical trials for new drugs have been delayed because researchers must also offer the older, short-supply medicines for comparison’s sake.
Lawmakers and health care officials are working to find solutions to the supply problem, including possibly stockpiling cancer medications the way the Centers for Disease Control and Prevention already does with antibiotics in case of terrorist attacks or natural disasters.
In the article below, The New York Times looks at the forces causing the problem. –BF
WAIT BEFORE YOU GO...The New York Times:
A crucial problem is disconnection between the free market and required government regulation. Prices for many older medicines are low until the drugs are in short supply; then prices soar. But these higher prices do little to encourage more supply, because it can be difficult and expensive to overcome the technical and regulatory hurdles. And if supplies return to normal, prices plunge.
Executives at Premier, a hospital buying cooperative, said that in April and May its members received hundreds of offers from obscure drug wholesalers to sell drugs in short supply at vastly inflated prices. Of the 636 offers that included a price, 45 percent were at least 10 times the normal rate and 27 percent were at least 20 times normal.
Such sales offers are legal as long as suppliers prove that they bought the drugs appropriately.
This year, the ground feels uncertain — facts are buried and those in power are working to keep them hidden. Now more than ever, independent journalism must go beneath the surface.
At Truthdig, we don’t just report what's happening — we investigate how and why. We follow the threads others leave behind and uncover the forces shaping our future.
Your tax-deductible donation fuels journalism that asks harder questions and digs where others won’t.
Don’t settle for surface-level coverage.
Unearth what matters. Help dig deeper.
Donate now.
Reports detail how Americans have been saddled with exorbitant bills following medical evaluations in the effort to contain the virus.
The agency designed a flawed test for COVID-19, then took weeks to find a fix for state and local labs. The consequences could be deadly.
Solidarity, not alienation born of ignorance, is the solution to the health crisis and the racist response to it.
Prosecutions spike in some states in the drive to “do something” about the nation’s opioid-addiction scandal.
The bill would provide $25 million for studying gun violence, ending a nearly two-decade-long federal ban on such research.
"Bitten" author Kris Newby presents her case that the U.S. military has weaponized ticks and unleashed them on an unsuspecting public.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.